A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection.

ABSTRACT:

Background

Primary cytomegalovirus (CMV) infection during pregnancy carries a risk of congenital infection and possible severe sequelae. There is no established intervention for preventing congenital CMV infection.

Methods

In this multicenter, double-blind trial, pregnant women with primary CMV infection diagnosed before 24 weeks' gestation were randomly assigned to receive a monthly infusion of CMV hyperimmune globulin (at a dose of 100 mg per kilogram of body weight) or matching placebo until delivery. The primary outcome was a composite of congenital CMV infection or fetal or neonatal death if CMV testing of the fetus or neonate was not performed.

Results

From 2012 to 2018, a total of 206,082 pregnant women were screened for primary CMV infection before 23 weeks of

SUBMITTER: Hughes BL 

PROVIDER: S-EPMC8363945 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature